Navigation Links
Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data,Selected for Scientific Highlights Program at the American Academy,of Neurology Meeting

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Mar 19, 2007 - Acorda Therapeutics (Nasdaq: ACOR) today announced that Andrew Goodman, M.D., Director of the Multiple Sclerosis Center at the University of Rochester, will present data from Acorda's MS-F203 Phase 3 clinical trial of Fampridine-SR in multiple sclerosis at the upcoming American Academy of Neurology (AAN) meeting. The platform presentation will take place on Wednesday May 2, 2007 at 4:15 pm Eastern Time (ET). This abstract was also selected to be part of the Scientific Highlights program, which spotlights the top five percent of the more than 1600 abstracts accepted for presentation at this meeting. The AAN meeting will take place at the Hynes Convention Center in Boston, MA.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeut
'"/>




Page: 1 2

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
3. Acorda Therapeutics to Host Analyst and Investor Reception
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:7/1/2015)... 1, 2015 ExeGi Pharma, a company focused ... announced today that it has been granted a product ... Products Directorate (NNHPD) to sell Visbiome™ in ... by Professor Claudio De Simone , MD, PhD ... Professor De Simone recently signed an exclusive agreement with ...
(Date:7/1/2015)... 2015 According to a new ... Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), ... Global Forecast to 2020", published by MarketsandMarkets, the Transfection ... $957.9 Million by 2020 with a CAGR of 7.2% ... market T ables and 33 F ...
(Date:7/1/2015)... Mass. , July 1, 2015 Boston Scientific ... discussing financial results and business highlights for the second quarter ... 8 a.m. ET. The call will be hosted ... and Dan Brennan , executive vice president and chief ... call will be available via the Boston Scientific website. Webcast ...
Breaking Medicine Technology:ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4Boston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 2
(Date:7/1/2015)... ... 2015 , ... There is nothing new about marriage debates ... laws governing sexuality since the first Pilgrims landed at Plymouth Rock. The mid-1870s, ... Cindy Safronoff reveals. Crossing Swords: Mary Baker Eddy vs. Victoria Claflin Woodhull and ...
(Date:7/1/2015)... Lewisberry, PA (PRWEB) , ... July 01, 2015 ... ... their purist natural forms, such as organically raised chickens and eggs. Eating organic ... Raising backyard chickens is cleaner and more environmentally friendly than production chicken farming. ...
(Date:7/1/2015)... ... ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod J. ... Set for March 6th - 8th, the 2016 meeting will be held at the ... fundamentals of nasal surgery through the most modern advancements and updates in rhinoplasty and ...
(Date:7/1/2015)... ... ... Did you know that infertility in men is more common than couples ... Center of Texas (AFCT) would like to talk about some natural ways to increase ... be a “woman’s issue,” male fertility factors can play a role in about 40% ...
(Date:7/1/2015)... ... , ... Convoy of Hope will partner with local businesses, churches, ... August 1, at Spring Lake Park High School. , During the celebration, Convoy of ... of goods and services including free food, health services, family portraits, job services, a ...
Breaking Medicine News(10 mins):Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 2Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 3Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 4Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2
... Trial of 16 patients saw 46% improvement in symptoms ... drug -- oral EN101antisense -- reduced the severity of ... , Myasthenia gravis (MG), which affects about 20 in ... muscles. Other symptoms may include double vision, drooping eyelids, ...
... a much greater risk of finger and toe deformities, , , FRIDAY, ... new parent does is count the baby,s fingers and toes. ... unhappy surprise, because smoking increases the odds that a baby will ... half a pack a day increased the risk of having a ...
... is accumulating on how bad stress is for ... a persons risk for developing central nervous system ... other inflammatory diseases, say researchers presenting at the ... (APA). These researchers have demonstrated for the first ...
... people now diagnosed as having depression? Two experts give their ... psychiatrist from Australia says the current threshold for what is ... fears it could lead to a diagnosis of depression becoming ... be depressed and points to his own cohort study which ...
... with chronic myeloid leukemia (CML) are treated first with ... protein known to cause the cancer (BCR-ABL). If their ... to the effects of imatinib, individuals are treated with ... in a different way. However, patients that relapse after ...
... 16, 2007 One in three people exposed to ... symptoms that may require treatment, according to research published ... American Dental Association. , Researchers at Ume University, Sweden, ... dysfunction in 60 patients in hospital emergency rooms directly ...
Cached Medicine News:Health News:Another Reason Not to Smoke While Pregnant: Birth Defects 2Health News:Another Reason Not to Smoke While Pregnant: Birth Defects 3Health News:New research shows how chronic stress worsens neurodegenerative disease course 2Health News:New research shows how chronic stress worsens neurodegenerative disease course 3Health News:Are too many people diagnosed as 'depressed?' 2
... operate with either one, eight, or twelve ... an imaging process to map the entire ... individual signals can overlap). The reader from ... containing 96 parallel micro-objectives. The 96 individual ...
... combine excellent specifications and performance with convenience ... powerful performance at a price much lower ... line includes several models with options that ... OEM users, including the ability to read ...
The DELFIA Platewash is a general purpose microtitration plate and strip washer especially standardized for use with DELFIA diagnostic kits....
Easy to use , Allow for a flexible washing , Uniform and efficient , Very robust and reliable , Adjustable to all well shapes , Rack included (not autoclavable) , Autoclavable at 121C , No e...
Medicine Products: